 Kavita Nair
Concepts (146)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Multiple Sclerosis | 5 | 2023 | 376 | 1.670 |
Why?
| | Insurance, Pharmaceutical Services | 6 | 2020 | 23 | 1.590 |
Why?
| | Drugs, Generic | 3 | 2021 | 18 | 1.490 |
Why?
| | Chronic Disease | 6 | 2020 | 1578 | 1.100 |
Why?
| | Managed Care Programs | 5 | 2011 | 133 | 1.020 |
Why?
| | Prescription Drugs | 2 | 2021 | 116 | 0.970 |
Why?
| | Choice Behavior | 2 | 2020 | 155 | 0.830 |
Why?
| | Cost Sharing | 3 | 2020 | 14 | 0.810 |
Why?
| | Nervous System Diseases | 2 | 2023 | 253 | 0.780 |
Why?
| | Insurance Benefits | 3 | 2010 | 11 | 0.770 |
Why?
| | Drug Costs | 1 | 2021 | 92 | 0.700 |
Why?
| | Health Services | 2 | 2009 | 103 | 0.600 |
Why?
| | Health Expenditures | 4 | 2012 | 171 | 0.540 |
Why?
| | Medicare Part D | 2 | 2021 | 26 | 0.540 |
Why?
| | Insurance Coverage | 2 | 2011 | 200 | 0.500 |
Why?
| | Insurance, Health | 3 | 2016 | 244 | 0.460 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 2 | 2012 | 299 | 0.420 |
Why?
| | Practice Patterns, Physicians' | 1 | 2021 | 1177 | 0.410 |
Why?
| | Gout Suppressants | 1 | 2012 | 20 | 0.410 |
Why?
| | Arthritis, Gouty | 1 | 2012 | 14 | 0.410 |
Why?
| | Absenteeism | 1 | 2012 | 40 | 0.400 |
Why?
| | Health Care Costs | 2 | 2012 | 381 | 0.390 |
Why?
| | Health Resources | 1 | 2012 | 122 | 0.370 |
Why?
| | Diagnostic Tests, Routine | 1 | 2011 | 87 | 0.350 |
Why?
| | Antibodies, Monoclonal | 3 | 2012 | 1262 | 0.330 |
Why?
| | Autoimmune Diseases | 1 | 2012 | 382 | 0.330 |
Why?
| | Health Benefit Plans, Employee | 1 | 2009 | 20 | 0.320 |
Why?
| | Immunologic Factors | 1 | 2011 | 220 | 0.320 |
Why?
| | Adrenal Cortex Hormones | 1 | 2012 | 497 | 0.320 |
Why?
| | Program Development | 1 | 2010 | 341 | 0.310 |
Why?
| | Loratadine | 2 | 2005 | 3 | 0.290 |
Why?
| | United States | 10 | 2023 | 12176 | 0.280 |
Why?
| | Nonprescription Drugs | 2 | 2005 | 68 | 0.270 |
Why?
| | Antirheumatic Agents | 1 | 2009 | 255 | 0.270 |
Why?
| | Antibodies, Monoclonal, Humanized | 3 | 2023 | 663 | 0.260 |
Why?
| | Drug Prescriptions | 3 | 2005 | 239 | 0.250 |
Why?
| | Infusions, Intravenous | 2 | 2023 | 371 | 0.240 |
Why?
| | Dyslipidemias | 1 | 2005 | 154 | 0.230 |
Why?
| | Medicare | 1 | 2009 | 665 | 0.220 |
Why?
| | Neurology | 2 | 2023 | 84 | 0.220 |
Why?
| | Prescription Fees | 1 | 2003 | 3 | 0.220 |
Why?
| | Quality Indicators, Health Care | 1 | 2005 | 287 | 0.210 |
Why?
| | Diabetes Mellitus | 2 | 2010 | 900 | 0.210 |
Why?
| | Humans | 23 | 2023 | 114623 | 0.210 |
Why?
| | Adult | 12 | 2023 | 30528 | 0.200 |
Why?
| | Male | 15 | 2023 | 55554 | 0.200 |
Why?
| | Middle Aged | 11 | 2020 | 26719 | 0.200 |
Why?
| | Patient Outcome Assessment | 1 | 2023 | 122 | 0.200 |
Why?
| | Multiple Sclerosis, Relapsing-Remitting | 1 | 2022 | 69 | 0.200 |
Why?
| | Metabolic Networks and Pathways | 1 | 2022 | 168 | 0.190 |
Why?
| | Information Services | 1 | 2001 | 44 | 0.190 |
Why?
| | Myeloid Cells | 1 | 2022 | 126 | 0.190 |
Why?
| | Insurance Claim Review | 2 | 2012 | 67 | 0.190 |
Why?
| | Female | 15 | 2023 | 59466 | 0.190 |
Why?
| | Retrospective Studies | 8 | 2023 | 12542 | 0.190 |
Why?
| | Neurologists | 1 | 2021 | 18 | 0.190 |
Why?
| | Community Participation | 1 | 2001 | 116 | 0.180 |
Why?
| | Dementia | 1 | 2023 | 187 | 0.180 |
Why?
| | Infliximab | 2 | 2012 | 94 | 0.180 |
Why?
| | Arthritis, Rheumatoid | 1 | 2009 | 1002 | 0.180 |
Why?
| | Attitude to Health | 1 | 2003 | 405 | 0.170 |
Why?
| | Patient Satisfaction | 1 | 2003 | 578 | 0.160 |
Why?
| | Aged | 9 | 2023 | 19061 | 0.160 |
Why?
| | B-Lymphocytes | 1 | 2022 | 766 | 0.150 |
Why?
| | Protein Kinase Inhibitors | 1 | 2022 | 785 | 0.140 |
Why?
| | Pharmaceutical Services | 2 | 2011 | 77 | 0.140 |
Why?
| | Models, Statistical | 1 | 2020 | 599 | 0.130 |
Why?
| | Drug Utilization Review | 3 | 2005 | 57 | 0.130 |
Why?
| | Medication Adherence | 2 | 2010 | 536 | 0.120 |
Why?
| | Ambulatory Care | 2 | 2023 | 478 | 0.120 |
Why?
| | Aged, 80 and over | 4 | 2016 | 6344 | 0.110 |
Why?
| | Young Adult | 4 | 2016 | 10455 | 0.110 |
Why?
| | Formularies as Topic | 2 | 2003 | 6 | 0.110 |
Why?
| | Population Surveillance | 1 | 2016 | 392 | 0.110 |
Why?
| | Contraindications | 1 | 2012 | 85 | 0.100 |
Why?
| | Cohort Studies | 3 | 2013 | 4894 | 0.100 |
Why?
| | Costs and Cost Analysis | 1 | 2012 | 195 | 0.100 |
Why?
| | Age Distribution | 1 | 2012 | 342 | 0.100 |
Why?
| | Mitoxantrone | 1 | 2011 | 12 | 0.100 |
Why?
| | Glatiramer Acetate | 1 | 2011 | 20 | 0.090 |
Why?
| | Hematologic Tests | 1 | 2011 | 22 | 0.090 |
Why?
| | Natalizumab | 1 | 2011 | 46 | 0.090 |
Why?
| | Interferon-beta | 1 | 2011 | 79 | 0.090 |
Why?
| | Financing, Personal | 1 | 2011 | 25 | 0.090 |
Why?
| | Poisson Distribution | 1 | 2010 | 71 | 0.090 |
Why?
| | Clinical Laboratory Techniques | 1 | 2011 | 87 | 0.090 |
Why?
| | Likelihood Functions | 1 | 2010 | 126 | 0.090 |
Why?
| | Spine | 1 | 2011 | 136 | 0.090 |
Why?
| | Respiratory Function Tests | 1 | 2011 | 522 | 0.080 |
Why?
| | Adolescent | 4 | 2016 | 17831 | 0.080 |
Why?
| | Preferred Provider Organizations | 1 | 2009 | 4 | 0.080 |
Why?
| | Analysis of Variance | 1 | 2012 | 1226 | 0.080 |
Why?
| | Orthopedic Procedures | 1 | 2011 | 208 | 0.080 |
Why?
| | Transportation | 1 | 2009 | 44 | 0.080 |
Why?
| | Private Sector | 1 | 2009 | 51 | 0.080 |
Why?
| | Regression Analysis | 2 | 2009 | 944 | 0.080 |
Why?
| | Pain Management | 1 | 2011 | 288 | 0.080 |
Why?
| | Surveys and Questionnaires | 1 | 2020 | 4620 | 0.080 |
Why?
| | North America | 1 | 2009 | 256 | 0.080 |
Why?
| | Electrocardiography | 1 | 2011 | 560 | 0.080 |
Why?
| | Research Design | 1 | 2014 | 928 | 0.070 |
Why?
| | Cost-Benefit Analysis | 2 | 2014 | 544 | 0.070 |
Why?
| | Proportional Hazards Models | 1 | 2011 | 1075 | 0.070 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2012 | 1139 | 0.070 |
Why?
| | Multivariate Analysis | 1 | 2010 | 1430 | 0.070 |
Why?
| | Patient Acceptance of Health Care | 1 | 2012 | 681 | 0.070 |
Why?
| | Severity of Illness Index | 1 | 2014 | 2537 | 0.070 |
Why?
| | Program Evaluation | 1 | 2010 | 822 | 0.070 |
Why?
| | Colorado | 2 | 2013 | 4099 | 0.070 |
Why?
| | Peptides | 1 | 2011 | 848 | 0.060 |
Why?
| | Logistic Models | 1 | 2010 | 1840 | 0.060 |
Why?
| | Anti-Allergic Agents | 1 | 2005 | 41 | 0.060 |
Why?
| | Efficiency, Organizational | 1 | 2005 | 125 | 0.060 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2009 | 1842 | 0.060 |
Why?
| | Benchmarking | 1 | 2005 | 161 | 0.060 |
Why?
| | Longitudinal Studies | 1 | 2011 | 2387 | 0.060 |
Why?
| | Cholesterol, LDL | 1 | 2005 | 307 | 0.060 |
Why?
| | Histamine H2 Antagonists | 1 | 2004 | 26 | 0.060 |
Why?
| | Hypoglycemic Agents | 1 | 2010 | 1008 | 0.050 |
Why?
| | Hyperlipidemias | 1 | 2003 | 121 | 0.050 |
Why?
| | Patient Compliance | 2 | 2003 | 524 | 0.050 |
Why?
| | Pamphlets | 1 | 2001 | 24 | 0.050 |
Why?
| | Evidence-Based Medicine | 1 | 2005 | 668 | 0.050 |
Why?
| | Risk Assessment | 1 | 2010 | 2967 | 0.050 |
Why?
| | Health Care Surveys | 1 | 2023 | 539 | 0.050 |
Why?
| | Students, Pharmacy | 1 | 2001 | 98 | 0.040 |
Why?
| | Hospitalization | 1 | 2009 | 1749 | 0.040 |
Why?
| | Magnetic Resonance Imaging | 1 | 2011 | 3039 | 0.040 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2003 | 373 | 0.040 |
Why?
| | Cross-Sectional Studies | 2 | 2023 | 4405 | 0.040 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2014 | 3244 | 0.040 |
Why?
| | Recurrence | 1 | 2020 | 935 | 0.040 |
Why?
| | Registries | 1 | 2023 | 1767 | 0.030 |
Why?
| | Decision Making | 1 | 2001 | 782 | 0.030 |
Why?
| | Quality-Adjusted Life Years | 1 | 2014 | 101 | 0.030 |
Why?
| | Medical Audit | 1 | 2013 | 75 | 0.030 |
Why?
| | Diabetes Complications | 1 | 2014 | 211 | 0.020 |
Why?
| | Child | 2 | 2023 | 18404 | 0.020 |
Why?
| | Databases, Factual | 1 | 2016 | 1124 | 0.020 |
Why?
| | Prevalence | 1 | 2016 | 2249 | 0.020 |
Why?
| | Comorbidity | 1 | 2014 | 1448 | 0.020 |
Why?
| | Rhinitis, Allergic, Perennial | 1 | 2005 | 23 | 0.020 |
Why?
| | California | 1 | 2005 | 353 | 0.010 |
Why?
| | Child, Preschool | 1 | 2016 | 9108 | 0.010 |
Why?
| | Coronary Disease | 1 | 2003 | 348 | 0.010 |
Why?
| | Risk Factors | 1 | 2003 | 8628 | 0.010 |
Why?
|
|
Nair's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|